Literature DB >> 29301923

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Guillaume Louvel1, Rastislav Bahleda2, Samy Ammari3, Cécile Le Péchoux4, Antonin Levy4, Christophe Massard2, Jérôme Le Pavec5, Stéphane Champiat2, Eric Deutsch4,2,3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29301923     DOI： 10.1183/13993003.01737-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  14 in total

1.  Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot.

Authors:  Garrett Kelly; Joshua J Milligan; Eric M Mastria; Sarah Kim; Stephanie R Zelenetz; Jarrett Dobbins; Leon Y Cai; Xinghai Li; Smita K Nair; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2022-01-22       Impact factor: 9.776

2.  Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.

Authors:  Eliana La Rocca; Michela Dispinzieri; Laura Lozza; Gabriella Mariani; Serena Di Cosimo; Massimiliano Gennaro; Riccardo Valdagni; Maria Carmen De Santis
Journal:  Med Oncol       Date:  2018-11-15       Impact factor: 3.064

3.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

Review 4.  Immunotherapy in non-small cell lung cancer: Update and new insights.

Authors:  Xabier Mielgo-Rubio; Eider Azkona Uribelarrea; Laura Quintanta Cortés; María Sereno Moyano
Journal:  J Clin Transl Res       Date:  2021-01-20

Review 5.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Authors:  Yu Chen; Min Gao; Zhaoqin Huang; Jinming Yu; Xiangjiao Meng
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

Review 6.  Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.

Authors:  Feifei Teng; Min Li; Jinming Yu
Journal:  BMC Med       Date:  2020-09-18       Impact factor: 8.775

Review 7.  Radiation-Induced Lung Injury-Current Perspectives and Management.

Authors:  Mandeep Singh Rahi; Jay Parekh; Prachi Pednekar; Gaurav Parmar; Soniya Abraham; Samar Nasir; Rajamurugan Subramaniyam; Gini Priyadharshini Jeyashanmugaraja; Kulothungan Gunasekaran
Journal:  Clin Pract       Date:  2021-07-01

Review 8.  The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.

Authors:  Alistair R Miller; Renee Manser
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 9.  Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?

Authors:  Mathieu Spaas; Yolande Lievens
Journal:  Front Med (Lausanne)       Date:  2019-11-07

Review 10.  Radiotherapy-immunotherapy combinations - perspectives and challenges.

Authors:  Michele Mondini; Antonin Levy; Lydia Meziani; Fabien Milliat; Eric Deutsch
Journal:  Mol Oncol       Date:  2020-03-13       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.